Results of 1940 embolizations for dural arteriovenous fistulas: Japanese Registry of Neuroendovascular Therapy (JR-NET3)

Restricted access

OBJECTIVE

Embolization is the most common treatment for dural arteriovenous fistulas (dAVFs). A retrospective, multicenter observational study was conducted in Japan to clarify the nature, frequency, and risk factors for complications of dAVF embolization.

METHODS

Patient data were derived from the Japanese Registry of Neuroendovascular Therapy 3 (JR-NET3). A total of 40,169 procedures were registered in JR-NET3, including 2121 procedures (5.28%) in which dAVFs were treated with embolization. After data extraction, the authors analyzed complication details and risk factors in 1940 procedures performed in 1458 patients with cranial dAVFs treated with successful or attempted embolization.

RESULTS

Transarterial embolization (TAE) alone was performed in 858 cases (44%), and transvenous embolization (TVE) alone was performed in 910 cases (47%). Both TAE and TVE were performed in one session in 172 cases (9%). Complications occurred in 149 cases (7.7%). Thirty-day morbidity and mortality occurred in 55 cases (2.8%) and 16 cases (0.8%), respectively. Non–sinus-type locations, radical embolization as the strategy, procedure done at a hospital that performed dAVF embolization in fewer than 10 cases during the study period, and emergency procedures were independent risk factors for overall complications.

CONCLUSIONS

Complication rates of dAVF embolization in Japan were acceptable. For better results, the risk factors identified in this study should be considered in treatment decisions.

ABBREVIATIONS ACF = anterior cranial fossa; CCJ = craniocervical junction; CMS = condylar-marginal sinus; CS = cavernous sinus; CVR = cortical venous reflux; dAVF = dural arteriovenous fistula; EVT = endovascular therapy; JR-NET = Japanese Registry of Neuroendovascular Therapy; mRS = modified Rankin Scale; NBCA = N-butyl-cyanoacrylate; SPS = superior petrosal sinus; SSS = superior sagittal sinus; TAE = transarterial embolization; TS/SS = transverse sinus–sigmoid sinus; TVE = transvenous embolization.

Downloadable materials

  • Supplemental Figs. 1 and 2 (PDF 352 KB)

Article Information

Correspondence Masafumi Hiramatsu: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. mhiramatsu@okayama-u.ac.jp.

INCLUDE WHEN CITING Published online June 28, 2019; DOI: 10.3171/2019.4.JNS183458.

Disclosures N. Sakai received unrelated consultancy from Achieva Co., Cardiatis Co., Cerenovus/Johnson & Johnson Co., Medtronic Co., MicroVention/Terumo Co., Penumbra Co., Stryker Co., and an unrelated research grant from Terumo Co. K. Iihara received unrelated research grants from Otsuka Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Kaneka Medix Co., Chugai Pharmaceutical Co., and Eizai Co. M. Hiramatsu, K. Sugiu, T. Hishikawa, S. Nishihiro, N. Kidani, Y. Takahashi, S. Murai, I. Date, N. Kuwayama, and T. Satow had no conflicts of interest to declare.

© AANS, except where prohibited by US copyright law.

Headings

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 288 288 68
Full Text Views 97 97 27
PDF Downloads 72 72 18
EPUB Downloads 0 0 0

PubMed

Google Scholar